[go: up one dir, main page]

SI1637517T1 - Derivat estra 2-aminobiciklo 3.1.0 heksan-2,6-dikarboksilne kisline - Google Patents

Derivat estra 2-aminobiciklo 3.1.0 heksan-2,6-dikarboksilne kisline

Info

Publication number
SI1637517T1
SI1637517T1 SI200431569T SI200431569T SI1637517T1 SI 1637517 T1 SI1637517 T1 SI 1637517T1 SI 200431569 T SI200431569 T SI 200431569T SI 200431569 T SI200431569 T SI 200431569T SI 1637517 T1 SI1637517 T1 SI 1637517T1
Authority
SI
Slovenia
Prior art keywords
hydrogen atom
hexane
ester derivative
dicarboxylic ester
aminobicyclo
Prior art date
Application number
SI200431569T
Other languages
English (en)
Inventor
Akito Yasuhara
Kazunari Sakagami
Hiroshi Ohta
Atsuro Nakazato
Original Assignee
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd
Publication of SI1637517T1 publication Critical patent/SI1637517T1/sl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/46Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C229/50Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups and carboxyl groups bound to carbon atoms being part of the same condensed ring system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C221/00Preparation of compounds containing amino groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87Benzo [c] furans; Hydrogenated benzo [c] furans
    • C07D307/88Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Addiction (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Detergent Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Furan Compounds (AREA)
SI200431569T 2003-06-26 2004-06-25 Derivat estra 2-aminobiciklo 3.1.0 heksan-2,6-dikarboksilne kisline SI1637517T1 (sl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2003181930 2003-06-26
JP2003373511 2003-10-31
JP2004128663 2004-04-23
EP04746867A EP1637517B1 (en) 2003-06-26 2004-06-25 2-aminobicyclo 3.1.0 hexane-2,6-dicarboxylic ester derivative
PCT/JP2004/009398 WO2005000791A1 (ja) 2003-06-26 2004-06-25 2-アミノ-ビシクロ[3.1.0]ヘキサン-2,6-ジカルボン酸エステル誘導体

Publications (1)

Publication Number Publication Date
SI1637517T1 true SI1637517T1 (sl) 2011-01-31

Family

ID=33556154

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200431569T SI1637517T1 (sl) 2003-06-26 2004-06-25 Derivat estra 2-aminobiciklo 3.1.0 heksan-2,6-dikarboksilne kisline

Country Status (20)

Country Link
US (5) US7960579B2 (sl)
EP (3) EP2287147B1 (sl)
JP (1) JP4792971B2 (sl)
KR (1) KR101071507B1 (sl)
AT (1) ATE487690T1 (sl)
AU (2) AU2004252017B2 (sl)
BR (1) BRPI0411823A (sl)
CA (1) CA2530706C (sl)
CY (1) CY1110997T1 (sl)
DE (1) DE602004030007D1 (sl)
DK (2) DK2123630T3 (sl)
ES (1) ES2394175T3 (sl)
HR (1) HRP20100619T1 (sl)
MX (1) MXPA05013740A (sl)
NO (1) NO335004B1 (sl)
NZ (2) NZ580554A (sl)
PL (1) PL1637517T3 (sl)
PT (1) PT1637517E (sl)
SI (1) SI1637517T1 (sl)
WO (1) WO2005000791A1 (sl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20100619T1 (hr) * 2003-06-26 2011-01-31 Taisho Pharmaceutical Co. Derivat 2-aminobiciklo[3.1.0]heksan-2,6-dikarboksilnog estera
TW201129700A (en) 2009-11-18 2011-09-01 Taisho Pharmaceutical Co Ltd Method for producing optically active bicyclo [310] hexane derivative using oxygen
JP5655791B2 (ja) * 2009-11-19 2015-01-21 大正製薬株式会社 3−アルコキシ−2−アミノ−6−フルオロビシクロ[3.1.0]ヘキサン−2,6−ジカルボン酸誘導体及びその中間体の製造方法
AR083845A1 (es) 2010-11-18 2013-03-27 Lilly Co Eli COMPUESTOS 3-FENILSULFANILMETIL-BICICLO[3.1.0]HEXANO 4-SUSTITUIDOS COMO ANTAGONISTAS DE mGluR2/3
WO2012068041A1 (en) 2010-11-18 2012-05-24 Eli Lilly And Company 4-SUBSTITUTED-3-BENZYLOXY-BICYCLO[3.1.0]HEXANE COMPOUNDS AS mGluR 2/3 ANTAGONISTS
WO2013062680A1 (en) * 2011-10-25 2013-05-02 Braincells, Inc. Novel compounds and compositions thereof for treating nervous system disorders
AR089718A1 (es) 2012-02-01 2014-09-10 Lilly Co Eli AGONISTAS DE mGlu2/3
JP5983713B2 (ja) * 2013-11-29 2016-09-06 大正製薬株式会社 含フッ素アミノ酸のプロドラッグを含有する医薬
FR3026843B1 (fr) * 2014-10-03 2016-11-18 Univ Pierre Et Marie Curie Paris 6 Procede de caracterisation du mecanisme de fissuration d'un materiau a partir de sa surface de rupture
HRP20211277T1 (hr) 2016-04-18 2021-11-12 Taisho Pharmaceutical Co., Ltd. Predlijek derivata aminokiseline
CN110191709A (zh) 2017-01-17 2019-08-30 德州大学系统董事会 可用作吲哚胺2,3-双加氧酶和/或色氨酸双加氧酶抑制剂的化合物
KR101877672B1 (ko) 2017-04-03 2018-07-11 엘에스산전 주식회사 Ad컨버터
WO2020018670A1 (en) * 2018-07-17 2020-01-23 Board Of Regents, The University Of Texas System Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase
US11501618B1 (en) * 2018-10-19 2022-11-15 Amazon Technologies, Inc. Security device with user-configurable motion detection settings
CN116444470B (zh) * 2023-03-29 2025-04-04 河南中烟工业有限责任公司 一种二羧酸二ddmp酯类化合物、制备方法及应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750566A (en) * 1994-08-12 1998-05-12 Eli Lilly And Company Synthetic excitatory amino acids
GB9605429D0 (en) * 1995-11-16 1996-05-15 Lilly Co Eli Excitatory amino acid receptor antagonists
ZA983930B (en) * 1997-05-14 1999-11-08 Lilly Co Eli Excitatory amino acid receptor modulators.
PT1110943E (pt) 1998-08-31 2004-08-31 Taisho Pharmaceutical Co Ltd Derivados 6-fluorobiciclo¬3.1.0|hexano
JP4194715B2 (ja) 1998-08-31 2008-12-10 大正製薬株式会社 6−フルオロビシクロ[3.1.0]ヘキサン誘導体
CH694053A5 (de) * 1998-09-03 2004-06-30 Hoffmann La Roche Verfahren zur Herstellung von 2-Amino-bicyclo[3.1.0]hexan-2,6-dicarbonsäure-Derivaten.
CN1216038C (zh) 2000-06-28 2005-08-24 大正制药株式会社 新型二羧酸衍生物
EP1370519A1 (en) 2001-02-22 2003-12-17 Eli Lilly And Company Synthetic excitatory amino acids
MXPA04006322A (es) * 2001-12-27 2004-10-04 Taisho Pharmaceutical Co Ltd Derivados de 6-fluorobiciclo[3.1.0]hexano.
JP2007063129A (ja) * 2003-06-26 2007-03-15 Taisho Pharmaceut Co Ltd 2−アミノ−3−アルコキシビシクロ[3.1.0]ヘキサン誘導体
US7381746B2 (en) * 2003-06-26 2008-06-03 Taisho Pharmaceutical Co., Ltd. 2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative
HRP20100619T1 (hr) * 2003-06-26 2011-01-31 Taisho Pharmaceutical Co. Derivat 2-aminobiciklo[3.1.0]heksan-2,6-dikarboksilnog estera

Also Published As

Publication number Publication date
KR20060024817A (ko) 2006-03-17
CY1110997T1 (el) 2015-06-11
DK1637517T3 (da) 2011-01-31
US8258133B2 (en) 2012-09-04
NO20060428L (no) 2006-03-10
MXPA05013740A (es) 2006-05-17
ES2394175T3 (es) 2013-01-23
WO2005000791A1 (ja) 2005-01-06
EP1637517A1 (en) 2006-03-22
AU2009217374B2 (en) 2011-03-03
NO335004B1 (no) 2014-08-25
JP4792971B2 (ja) 2011-10-12
PL1637517T3 (pl) 2011-04-29
JPWO2005000791A1 (ja) 2006-10-19
CA2530706C (en) 2012-11-27
KR101071507B1 (ko) 2011-10-10
EP2123630A1 (en) 2009-11-25
NZ544131A (en) 2009-11-27
US20120028982A1 (en) 2012-02-02
US8350060B2 (en) 2013-01-08
EP1637517A4 (en) 2007-05-23
EP2123630B1 (en) 2012-07-25
EP2287147A3 (en) 2011-05-18
AU2009217374A1 (en) 2009-10-08
EP2287147A2 (en) 2011-02-23
HK1095318A1 (zh) 2007-05-04
CA2530706A1 (en) 2005-01-06
DE602004030007D1 (en) 2010-12-23
US8076502B2 (en) 2011-12-13
US20100298561A1 (en) 2010-11-25
AU2004252017A1 (en) 2005-01-06
BRPI0411823A (pt) 2006-08-08
US20090306408A1 (en) 2009-12-10
PT1637517E (pt) 2011-01-31
HRP20100619T1 (hr) 2011-01-31
NZ580554A (en) 2011-01-28
US8039647B2 (en) 2011-10-18
US20070021394A1 (en) 2007-01-25
US7960579B2 (en) 2011-06-14
DK2123630T3 (da) 2012-10-22
EP1637517B1 (en) 2010-11-10
EP2287147B1 (en) 2013-05-15
AU2004252017B2 (en) 2009-10-08
US20120004232A1 (en) 2012-01-05
ATE487690T1 (de) 2010-11-15

Similar Documents

Publication Publication Date Title
PL1637517T3 (pl) Pochodne estrowe kwasu 2-aminobicyklo[3.1.0]heksano-2,6-dikarboksylowego
MY139357A (en) Novel benzoimidazole derivatives useful as antiproliferative agents
GEP20022676B (en) 4-Phenyl-Pyridine Derivatives, Method for Their Production and Their Use for Treatment of Disorders Caused by Antagonist of NK-1 Receptors
MX2007004183A (es) Derivados de benzoimidazol utiles como agentes antiproliferacion.
AU2002239463A1 (en) Cyclopenta(b)(1,4) diazepino(6,7,1-hi)indoles as 5ht2c antagonists
NZ515894A (en) Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases
AP1895A (en) Novel benzoimidazole derivatives useful as antiproliferative agents.
SG155938A1 (en) Novel pyridinone derivatives and their use as positive allosteric modulators of mglur2-receptors
BRPI0413876A (pt) tienopiridin-fenilacetamidas e seus derivados úteis como agentes antiangiogênicos
TW200726765A (en) Triazolopyridine cannabinoid receptor 1 antagonists
MX2008001152A (es) Benzimidazoles triciclicos y su uso como moduladores del receptor de glutamato metabotropico.
TW200642685A (en) Novel spiroindoline or spiroisoquinoline compounds, methods of use and compositions thereof
TWI265928B (en) A61k 31/4025 200601 a i htw a61p 25/00 200601 a n htw
AP2002002664A0 (en) Cyclohexylamine derivative as subtype selective NMDA receptor antagonists.
MY138547A (en) N-substituted nonaryl-heterocyclic nmda/nr2b antagonists
ATE171374T1 (de) Verwendung von 1-(aminoalkyl)-3-quinoxalin-2-on derivaten zur herstellung von neuroprotektiven mitteln
MY122731A (en) 4-phenyl-pyrimidine derivatives
TW200633984A (en) Amide compounds and activators of thrombopoietin receptor
MXPA05006271A (es) Metodo para el tratamiento de desordenes del movimiento usando derivados de acido barbiturico.
NZ533358A (en) 3,4-Dihydro-1H-isoquinolin-2-yl-derivatives for use as NK2 receptor antagonists
TW200637552A (en) Macrocyclic analogs for the treatment of immunoregulatory disorders and respiratory diseases
DE60135016D1 (de) Indolderivate und deren verwendung in medikamenten
MX2009005676A (es) Dialquilamino alquil esteres de pivagabina como medicamentos para el tratamiento de alteraciones del sistema nervioso central.
EP1650191A4 (en) THERAPEUTIC AGENT FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND METHOD OF TREATMENT FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE USING THE SAME
TW200519099A (en) Novel amines as histamine-3 receptor ligands and their therapeutic applications